Clinical trials
Completed Lymphoma, Large B-Cell, Diffuse trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
92 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 5 |
| 2004 | 4 |
| 2005 | 4 |
| 2007 | 7 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 6 |
| 2012 | 7 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 6 |
| 2016 | 8 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 92 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma Study Association | 9 |
| Celgene | 8 |
| Novartis Pharmaceuticals | 7 |
| European Organisation for Research and Treatment of Cancer - EORTC | 6 |
| The Lymphoma Academic Research Organisation | 6 |
| MorphoSys AG | 4 |
| Hoffmann-La Roche | 3 |
| Hospices Civils de Lyon | 3 |
| MedImmune LLC | 3 |
| Regeneron Pharmaceuticals | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, Large B-Cell, Diffuse | 92 |
| Lymphoma | 27 |
| Lymphoma, Follicular | 26 |
| Lymphoma, Non-Hodgkin | 25 |
| Recurrence | 16 |
| Lymphoma, Mantle-Cell | 14 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 13 |
| Lymphoma, B-Cell | 13 |
| Lymphoma, B-Cell, Marginal Zone | 12 |
| Burkitt Lymphoma | 10 |
Trials
Showing 1 to 25 of 92. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.